You are here: Industry Insights > Market News > Dr Reddy’s launch Fluphenazine Hydrochloride Tablets in US

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

Dr Reddy’s launch Fluphenazine Hydrochloride Tablets in US

expresspharmaFebruary 20, 2021

Tag: Dr Reddy’s , Fluphenazine Hydrochloride Tablets , Prolixin

Favorites

Dr Reddy’s Laboratories announced the launch of Fluphenazine Hydrochloride Tablets, USP,a therapeutic equivalent generic version of Prolixin Tablets, 1mg, 2.5mg, 5mg, and 10mg, approved by the US Food and Drug Administration (USFDA).

Fluphenazine hydrochloride is a trifluoromethyl phenothiazine derivative intended for the management of schizophrenia.

The Prolixin brand and generic had U.S. sales of approximately $134 million MAT for the most recent twelve months ending in December 2020 according to IQVIA Health.

Dr Reddy’s Fluphenazine Hydrochloride Tablets, USP are available in 1mg, 2.5mg, 5mg, and 10mg tablets in 100 bottle count sizes.

Previous:Brexit deal offers UK access to research and innovation program worth €95.5 bn: GlobalData

Next:South African variant may weaken vaccine protection: Pfizer

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Dr Reddy’s launch Fluphenazine Hydrochloride Tablets in US | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Dr Reddy’s launch Fluphenazine Hydrochloride Tablets in US

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Dr Reddy’s launch Fluphenazine Hydrochloride Tablets in US

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>